Canada· CA-DIN-02523434
JEMPERLI
A dostarlimab product containing dostarlimab, registered in Canada by GLAXOSMITHKLINE INC. The same ATC class is registered in 12 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Dostarlimab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FF07 (dostarlimab), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Dostarlimab · ATC L01FF07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- DOSTARLIMAB
- Manufacturer
- GLAXOSMITHKLINE INC
- Country
- Canada (CA)
- ATC code
- L01FF07
- ATC class
- Dostarlimab
- Defined daily dose
- 24 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dostarlimab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandJEMPERLIGlaxoSmithKline Trading Services Limited
- SpainJEMPERLI 500 mg CONCENTRADO PARA SOLUCION PARA PERFUSIONGlaxosmithkline Trading Services Limited
- CzechiaJEMPERLIGlaxoSmithKline Trading Services Limited, Dublin
- FranceJEMPERLI 500 mg, solution à diluer pour perfusionGLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- United KingdomJemperli 500mg/10ml concentrate for solution for infusion vialsGlaxoSmithKline UK Ltd
- IrelandJEMPERLI 500 mg concentrate for solution for infusionGlaxoSmithKline Trading Services Limited
- IcelandJemperliGlaxoSmithKline Trading Services Limited
- NetherlandsJemperli 500 mg oplossing voor infusieGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jemperli
- Liechtenstein · Jemperli
- Norway · Jemperli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/73d24f79-3bb4-4bc4-a9e4-976aa7f293c4 GET /v1/drugs/73d24f79-3bb4-4bc4-a9e4-976aa7f293c4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02523434",
"form": "SOLUTION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01FF07",
"schedule": [
"Schedule D",
"Prescription"
],
"drug_code": "101252",
"strengths": [
"50 MG"
],
"ahfs_class": null,
"substances": [
"DOSTARLIMAB"
],
"product_categorization": null
}See everything about dostarlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.